Industry News
Biotechnology Industry News
Takeda President of Research and…
Takeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.
The FDA has put enrollment in…
The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent tests, dealing a blow to an asset covered by a pending $350 million deal.
Frazier Life Sciences (FLS) has…
Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion for its long-running public fund.
Andy Plump, M.D., Ph.D., president…
Andy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.
It may have seemed like an…
It may have seemed like an ordinary Wednesday afternoon at MassBio’s headquarters in Technology Square, but the black SUV parked outside was a telltale sign that the Cambridge, Massachusetts-based biotech trade group was playing host
The future of NAMs depends on more…
The future of NAMs depends on more than innovation. Learn how sourcing, standards and evidence can accelerate adoption.
Luma Group announced the final…
Luma Group announced the final close of its inaugural life sciences venture capital fund totaling $410 million.
Neuro-focused Encoded Therapeutics…
Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up its internal manufacturing capabilities.
Tyra Biosciences has reported…
Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premarket trading after the
Kura Oncology has spun out a…
Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment.
A phase 2 trial of Beeline…
A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
Evommune’s MRGPRX2 antagonist…
Evommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for any itch-related conditions.
Solstice Oncology has secured $225…
Solstice Oncology has secured $225 million in series A funds to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care.
Schrödinger announced the launch…
Schrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.
With a detailed data drop that…
With a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic
Spyre’s three-pronged approach to…
Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
Pharvaris’ deucrictibant has…
Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients as the Swiss biotech awaits an FDA approval decision.
A pivotal trial of Bristol Myers…
A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multiple myeloma market.
The phase 3 Harbor trial of…
The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Biosciences. The flop
Inhibrx Biosciences’ CEO has…
Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s durability in treating head and neck cancer.